KRAS and neoplasm: The level of ctDNA is lower in patients without tumor metastasis, and this test also allows for the detection of mutations associated with a higher potential for distant spread—a KRAS mutation was detected in 58.9% of patients with disseminated disease and only in 18.2% of patients with locoregionally advanced disease [44,45].